AstraZeneca’s Akt inhibitor successful in phase III study in breast cancer
ADC评论
October 27, 2022
On October 26, AstraZeneca announced that the Phase III CAPItello-291 study of its Akt1/2/3 inhibitor capivasertib in combination with fulvestrant in breast cancer patients met
